![]() |
|
|
Department of Pharmacology and Toxicology, The Liver Center,
Comprehensive Cancer Center, Division of Clinical Pharmacology,
University of Alabama at Birmingham (L.P., E.C.S., M.P., J.-P.S.), and
Centre de Recherche Agronomique, Equipe INSERM (G.D.S., R.R)
The biotransformation of TNP-470
[O-(chloroacetylcarbamoyl)fumagillol; AGM 1470], a potent
in vitro inhibitor of angiogenesis, was investigated in
primary cultured hepatocytes isolated from different species, including
monkey, dog, and rat, as well as in microsomal fractions of various
monkey tissues. Previous metabolic studies by our group using human
hepatocytes in primary culture demonstrated that TNP-470 was primarily
metabolized to M-IV through an ester cleavage, with subsequent
conversion of M-IV to M-II by microsomal epoxide hydrolase. Additional
studies using monkey liver microsomes demonstrated that M-II was then
glucuronidated by uridine-5
-diphosphoglucuronyl transferase, leading
to the formation of M-III. Three other, as yet unidentified,
metabolites, labeled M-I, M-V, and M-VI, were also detected. Similarly
to findings in human hepatocytes, the predominant extracellular
metabolite was M-II in all species studied. Minor interspecies
variability was observed in the total amount of drug biotransformed by
hepatocytes, but some variability was detected in the metabolic pattern
of TNP-470 in monkey hepatocytes, compared with rat or dog hepatocytes. In monkey hepatocytes, as previously observed in human cells, TNP-470
was metabolized to six derivatives, labeled M-I, M-II, M-III, M-IV,
M-V, and M-VI, whereas the latter metabolite was not observed in dog or
rat extracellular medium. Extrahepatic metabolism of TNP-470 was also
studied using monkey intestine, kidney, and lung microsomes, which
demonstrated that, under these experimental conditions, TNP-470 was
extensively metabolized to four derivatives, i.e. M-I,
M-II, M-III, and M-IV, with M-III being detected only in liver samples.
These studies suggest that the metabolism of TNP-470 in monkeys appears
to be most closely related to that observed in humans. Although the
individual quantitative metabolic profiles were quite different in
various animal species, only one metabolite, namely M-VI, was not
detected in either dog or rat hepatocytes in vitro.
This article has been cited by other articles:
![]() |
C. Li, N. Chauret, L. A. Trimble, D. A. Nicoll-Griffith, J. M. Silva, D. MacDonald, H. Perrier, J. A. Yergey, T. Parton, R. P. Alexander, et al. Investigation of the in Vitro Metabolism Profile of a Phosphodiesterase-IV Inhibitor, CDP-840: Leading to Structural Optimization Drug Metab. Dispos., March 1, 2001; 29(3): 232 - 241. [Abstract] [Full Text] |
||||
![]() |
L. Placidi, E. C. Scott, D. Eckoff, S. Bynon, and J.-P. Sommadossi Metabolic Drug Interactions between Angiogenic Inhibitor, Tnp-470 and Anticancer Agents in Primary Cultured Hepatocytes and Microsomes Drug Metab. Dispos., May 1, 1999; 27(5): 623 - 626. [Abstract] [Full Text] |
||||